June 6-9, 2012, in Berlin, Germany

Company (Location)

Product

Description

Indication

Status

Date


Abbott (Abbott Park, Ill.)

Humira

Adalimumab

Rheumatoid arthritis

Data from two long-term, open-label studies showed that Humira treatment for up to 10 years continued to maintain improvement in disease activity

6/7/12

BioCryst Pharmaceuticals Inc. (Research Triangle Park, N.C.)

BCX4208

Enzyme inhibitor

Gout

Phase IIb data showed it undergoes renal elimination, is not metabolized by liver cells and does not induce or inhibit CYP isoforms or common drug transporters

6/7/12

Bristol-Myers Squibb Co. (New York)

Orencia

Abatacept

Rheumatoid arthritis

Met its primary endpoint, as measured by noninferiority, and demonstrated that when used with methotrexate it achieved comparable rates of efficacy to Humira

6/7/12

Genentech Inc. (South San Francisco)

Actemra

Tocilizumab; single-agent treatment

Rheumatoid arthritis

Data showed that adult RA patients who received Actemra experienced a significantly greater improvement in disease activity after 24 weeks compared to patients who received Humira

6/7/12

Janssen Research & Development LLC (unit of New Brunswick, N.J.-based Johnson & Johnson)

Stelara

Ustekinumab

Active psoriatic arthritis

Phase III data showed that it experienced significant improvements in signs and symptoms of the disease

6/7/12

Savient Pharmaceuticals Inc. (East Brunswick, N.J.)

Krystexxa

Pegloticase; pegylated uric acid specific enzyme

Chronic kidney disease

Data showed there was no difference in rates of response to Krystexxa by CKD stage and that it did not affect estimated glomerular filtration rate levels in patients with or without CKD

6/7/12


Notes:

The date indicated refers to the BioWorld Today issue in which the news item can be found.